NCT Number: NCT00140881
A Study to Determine the Effect of Montelukast Sodium as an Episode Modifier in the Treatment of Infrequent Episodic Asthma in Children (0476-165)
A 53-week study to determine the effect of montelukast sodium when given to children (with infrequent episodic asthma) at the earliest symptoms of an acute episode of asthma.
Looking for future studies?
Notify MeKey information
Conditions
Age range
2 year–14 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Males or females between the ages of 2 and 14 who have infrequent episodic asthma.
Treatment and study plan
Comparator: placebo
DrugPrimary outcomes
-
Composite unscheduled acute health care resource utilisation (specific for asthma; unscheduled visits, GP attendance, ED attendance and hospital admission).
Secondary outcomes
-
Parent/caregiver QOL endpoints.
-
The safety and tolerability of montelukast when use as an episode modifier.
-
The duration and severity of the episode assessed by the parent/caregiver symptom score and the use of b-agonist and oral corticosteroid.
Sponsors and collaborators
Lead sponsor
Organon and Co
Industry
Registry information
Official study title
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Determine the Effect of Montelukast Sodium as an Episode Modifier in the Treatment of Infrequent Episodic Asthma in Children
Important dates
- Study start
- 2000
- Primary completion
- 2003
- Study completion
- 2003
- First posted
- Sep 1, 2005
- Registry last updated
- Aug 14, 2024
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Bioequivalence Study of Budesonide/Formoterol Inhalation Powder in Healthy Participants
NCT07804303
Asthma, Bronchial Diseases
Nanjing, Jiangsu, China
View Trial DetailsInhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD)
NCT01721291
Asthma, Bronchial Diseases
London, United Kingdom
View Trial DetailsEvaluate Pharmacokinetics and Safety of Slow Release DHEA
NCT05623059
Asthma, Bronchial Diseases
Indianapolis, Indiana, United States
View Trial DetailsAgricultural Health Study Follow-up
NCT01399411
Asthma, Autoimmune Diseases
Iowa City, Illinois, United States
View Trial Details